E-mail not displaying correctly? View it in your browser.
Our Products
& Services

Click to find
more about our

In this newsletter

New technical note: Measure apoptosis in 3D microtissues with Promega’s assay
Now you can measure caspase-3/7 activity in 3D microtissues using Promega's Caspase-Glo® 3/7 assay. View technical note.

Join our workshop on 3D cell culture in Manchester on Sep 7 - register here!
InSphero’s next half-day workshop brings together experts on 3D cell culture and in vitro toxicology. The speaker panel includes James Sidaway (AstraZeneca) and Philip Hargreaves (Promega) View the program here or register by e-mail now! Registration deadline is Aug 27.

*50% discount for ELRIG Drug Discovery 2012 participants* Visit the InSphero stand (G3) at Drug Discovery 2012 to request a 50% discount voucher for this workshop!

InSphero coordinates EU project for next-generation drug screening device
InSphero will co-develop "The-Body-on-a-Chip" device with inter-connected microtissue models for early stage compound de-risking. On board are AstraZeneca, ETH Zurich, Ifado Dortmund, and KU Leuven.  Read more here.

3D cell culture literature picks – July 2012
Our applications team has reviewed a small selection of current 3D-cell-culture journal papers  to keep you updated about recent developments in 3D.

Meet InSphero at fairs & events
Meet the InSphero team at upcoming fairs, conferences and workshops to learn how 3D microtissues accelerate the process of drug discovery and development. Arrange a meeting, a webinar or register for a workshop.
About InSphero

InSphero is a leading supplier of organotypic, biological in-vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 6 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero’s 3D microtissues are scaffold free, highly reproducible and delivered in an automation-compatible 96-well format to replace conventional 2D cell assays for better biological relevance and predictivity. The 3D cancer microtissues reflect tumor physiology and are used routinely for screening. For toxicology and metabolics applications, rat and human 3D liver microtissues predict even rare cases of idiosyncratic toxicology and remain viable for more than 5 weeks for chronic studies. InSphero’s off-the-shelf portfolio of assay-ready microtissues is complemented by custom-made 3D microtissues with a development time of 4-6 weeks and production turnaround of less than 10 days.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich. The company was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award, CTIstartup certification and the SLAS New Product Award (NPA) 2011 Designation. InSphero is also officially certified to the ISO 9001:2008 standard for its Quality Management System.

Our mailing address is:
InSphero Inc.
74 Orion St
Brunswick, ME 04011-5031

Copyright (C) 2012 InSphero Inc. All rights reserved.